EUVIMEDEUVIMED entdecken
CrossrefInfokarte

The recognition pathway: reconceiving inventorship and obviousness for iterative CRISPR-AI convergence

Hassan Abdulhakim Bahebe, Li Xiaoming

Journal of Law and the Biosciences · 2026-07-07 · 13 (2)

DOI: 10.1093/jlb/lsag028 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Clustered Regularly Interspaced Short Palindromic Repeats -Artificial Intelligence (CRISPR-AI) convergence generate therapeutic candidates via iterative human-machine workflows that disrupt the inventorship criterion of patent law based on conception. In CRISPR-AI studies, AI systems suggest thousands of guide RNAs or Cas variants; human researchers select, confirm, and optimize them via experimental feedback loops that conceal the locus of conception. The existing patent doctrine, which demands a clear and final concept in the human mind, fails to align with inventions in which AI comes up with solutions that human researchers had not anticipated. This Article advances a recognition pathway for CRISPR-AI inventorship that maintains the natural-person baseline while attributing inventorship to humans who exercise claim-defining technical judgment in identifying patentable value within AI outputs. The Article reconceives the person having ordinary skill in the art standard for AI-enhanced biotechnology, rejecting both inflexible pre-AI baselines and the 'computer having ordinary skill in the art' proposal. A five-factor test is employed to assess AI-generated CRISPR inventions on non-obviousness in terms of problem structure, predictability of solutions, and quality of human judgment. The framework provides a computational biotechnology human-accountability grammar that is administrable, but not legally granted to machines.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →